Multiple myeloma: open trials in Portugal

14 open trials have a site in Portugal. Registry data; only the trial team decides who can take part.

NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
CCAB Centro Clinico Academico Braga Associacao, Braga · Champalimaud Clinical Centre, Lisbon · University Of Porto, Porto · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-11-03
NCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Uls Braga - Hosp. Braga, Braga · IPO Lisboa, Lisbon · Hosp. Cuf Descobertas, Lisbon · Uls Santo Antonio - Hosp. Santo Antonio, Porto · Uls Sao Joao - Hosp. Sao Joao, Porto · Uls Gaia Espinho, Vila Nova de Gaia
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Uls Braga - Hosp. Braga, Braga · Fund. Champalimaud, Lisbon · IPO Porto, Porto · Ulstmad - Hosp. Sao Pedro de Vila Real, Vila Real
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Hospital de Braga, Braga · Champalimaud Foundation, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-29
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
CCAB Centro Clinico Academico Braga Associacao, Braga · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-10-27
2026-526654-14-01
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Trial Treatment · Phase 3 · Janssen Cilag International
CCAB Centro Clinico Academico Braga Associacao, Braga · Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Champalimaud Clinical Centre, Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E., Vila Real
Registry updated 2026-10-14
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Champalimaud Clinical Centre, Lisbon · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia · Unidade Local De Saude De Tras-Os-Montes E Alto Douro E.P.E., Vila Real
Registry updated 2026-10-07
2025-524793-42-00
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Cilag International
CCAB Centro Clinico Academico Braga Associacao, Braga · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital Cuf Descobertas S.A., Lisbon · Unidade Local de Saude de Sao Joao E.P.E., Porto · Unidade Local De Saude De Santo Antonio E.P.E., Porto · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-09-11
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
CCAB Centro Clinico Academico Braga Associacao, Braga · Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Hospital da Luz, S.A, Lisbon · Unidade Local de Saúde de Gaia/Espinho, E. P. E, Vila Nova de Gaia
Registry updated 2026-08-24
NCT07728188
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · AbbVie
2CA-Braga, Hospital de Braga /ID# 283828, Braga · Centro Hospitalar De Lisboa Ocidental - Hospital De Sao Francisco Xavier /ID# 283500, Lisbon · Unidade Local de Saude Sao Joao /ID# 283530, Porto · Unidade Local de Saude de Gaia/Espinho /ID# 283492, Vila Nova de Gaia
Registry updated 2026-07-27
2025-525105-20-00
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie Deutschland GmbH & Co. KG
CCAB Centro Clinico Academico Braga Associacao, Braga · Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon · Instituto Portugues de Oncologia do Porto Francisco Gentil, E.P.E., Porto
Registry updated 2026-07-15
NCT06932562
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Trial Treatment · Phase 3 · European Myeloma Network B.V.
Unidade Local de Saúde de Coimbra, E.P.E., Coimbra · Unidade Local De Saude De Santo Antonio E.P.E., Porto
Registry updated 2026-03-25
NCT06237803
European Myeloma Network (EMN) Sample Project
Research · European Myeloma Network B.V.
CHUC, Coimbra · Fundacao Champalimaud, Lisbon · Chsj - Hosp. Sao Joao, Porto · IPOP Porto, Porto
Registry updated 2025-12-03

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error